Researcher Profile

Researcher Profile

Valerie Brown, MD, PhD

Valerie Brown, MD, PhD

Professor, Department of Pediatrics
Division of Hematology and Oncology
Scientific Program:Next-Generation Therapies
Disease Teams:
Pediatric Cancer

Research Interests

  • Transplants
  • Therapeutics
  • Hematopoietic Stem Cell Transplantation
  • Leukemia
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • Pediatrics
  • Survival
  • Child
  • Allogeneic Cells
  • Infections
  • Cell Transplantation
  • Bone Marrow

Clinical Trials

Protocol for a Research Database for Hematopoietic Cell Transplantation, other Cellular Therapies and Marrow Toxic Injuries.
A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia
A Phase I/II Study of Neratinib in Pediatric Patients with Relapsed or Refractory Solid Tumors or Hematologic Malignancies
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-RiskWNT-Driven Medulloblastoma Patients
A Phase I/II, Multicenter, Open-Label, Multi-Arm Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Activity of Idasanutlin in Combination with either Chemotherapy or Venetoclax in the Treatment of Pediatric and Young Adult Patients with Relapsed/Refractory Acute Leukemias or Solid Tumors
Phase 1 Study To Evaluate the Safety and Pharmacokinetics of Palbociclib (Ibrance®) in Combination with Irinotecan and Temozolomide in Pediatric Patients with Recurrent or Refractory Solid Tumors
Managed Access Program (MAP) to provide access to CTL019, for acute lymphoblastic leukemia (ALL) or large B-cell lymphoma patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release
A Phase 1/2, Open-label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects with Advanced or Metastatic Malignancies Harboring ALK, ROS1, or NTRK1-3 Alterations
Phase II Trial of Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications
A Phase III Randomized, Open Label, Multi-center Study of the Safety and Efficacy of Apixaban for Thromboembolism Prevention Versus No Systemic Anticoagulant Prophylaxis During Induction Chemotherapy in Children With Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoma (T or B Cell) Treated With Asparaginase
A Pilot Study Using Molecular Guided Therapy with Induction Chemotherapy Followed by Maintenance with DFMO for Subjects with Newly Diagnosed High-Risk Neuroblastoma
NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)
Protocol for a Research Sample Repository for Allogeneic Hematopoietic Stem Cell Transplantation

Recent Publications


Center for International Blood and Marrow Transplant Research Immunobiology Working Committee 2021, 'Genetics of HLA Peptide Presentation and Impact on Outcomes in HLA-Matched Allogeneic Hematopoietic Cell Transplantation', Transplantation and Cellular Therapy, vol. 27, no. 7, pp. 591-599.
Shah, N, Rakszawski, K, Nickolich, M, Ehmann, C, Wirk, B, Naik, S, Rybka, W, Zheng, H, Mierski, J, Silar, B, Mackey, G, Greiner, R, Brown, V, Claxton, D, Mineishi, S & Minagawa, K 2021, 'Improved outcome in AML relapse after allogeneic transplant with high-intensity chemotherapy followed by 2nd allogeneic stem cell transplant or donor lymphocyte infusion', Annals of Hematology, vol. 100, no. 10, pp. 2585-2592.


Lewis, EC, Kraveka, JM, Ferguson, W, Eslin, D, Brown, VI, Bergendahl, G, Roberts, W, Wada, RK, Oesterheld, J, Mitchell, D, Foley, J, Zage, P, Rawwas, J, Rich, M, Lorenzi, E, Broglio, K, Berry, D & Saulnier Sholler, GL 2020, 'A subset analysis of a phase II trial evaluating the use of DFMO as maintenance therapy for high-risk neuroblastoma', International Journal of Cancer, vol. 147, no. 11, pp. 3152-3159.
Dandoy, CE, Kim, S, Chen, M, Ahn, KW, Ardura, MI, Brown, V, Chhabra, S, Diaz, MA, Dvorak, C, Farhadfar, N, Flagg, A, Ganguly, S, Hale, GA, Hashmi, SK, Hematti, P, Martino, R, Nishihori, T, Nusrat, R, Olsson, RF, Rotz, SJ, Sung, AD, Perales, MA, Lindemans, CA, Komanduri, KV & Riches, ML 2020, 'Incidence, Risk Factors, and Outcomes of Patients Who Develop Mucosal Barrier Injury-Laboratory Confirmed Bloodstream Infections in the First 100 Days After Allogeneic Hematopoietic Stem Cell Transplant', JAMA network open, vol. 3, no. 1, pp. e1918668.
Camacho-Bydume, C, Wang, T, Sees, JA, Fernandez-Viña, M, Abid, MB, Askar, M, Beitinjaneh, A, Brown, V, Castillo, P, Chhabra, S, Gadalla, SM, Hsu, JM, Kamoun, M, Lazaryan, A, Nishihori, T, Page, K, Schetelig, J, Fleischhauer, K, Marsh, SGE, Paczesny, S, Spellman, SR, Lee, SJ & Hsu, KC 2020, 'Specific Class I HLA Supertypes but Not HLA Zygosity or Expression Are Associated with Outcomes following HLA-Matched Allogeneic Hematopoietic Cell Transplant: HLA Supertypes Impact Allogeneic HCT Outcomes', Biology of Blood and Marrow Transplantation.


Papanicolaou, GA, Ustun, C, Young, JAH, Chen, M, Kim, S, Woo Ahn, K, Komanduri, K, Lindemans, C, Auletta, JJ, Riches, ML, Abdel-Azim, H, Ahmed, IA, Aljurf, M, Antin, J, Ballen, KK, Beitinjaneh, A, Brown, VI, Cerny, J, Champlin, R, Chao, N, Chhabra, S, Dahi, PB, Daly, A, Dandoy, C, Dvorak, CC, Forman, S, Ganguly, S, Hashmi, SK, Kharfan-Dabaja, MA, Lazarus, H, Ljungman, P, Malone, AK, Murthy, G, Nishihori, T, Page, K, Pingali, RSR, Reddy, V, Saad, A, Savani, BN, Seftel, M, Szer, J, Vij, R, Weisdorf, D, William, BM, Williams, K, Wirk, B & Yared, J 2019, 'Bloodstream Infection Due to Vancomycin-resistant Enterococcus Is Associated with Increased Mortality after Hematopoietic Cell Transplantation for Acute Leukemia and Myelodysplastic Syndrome: A Multicenter, Retrospective Cohort Study', Clinical Infectious Diseases, vol. 69, no. 10, pp. 1771-1779.
Ustun, C, Kim, S, Chen, M, Beitinjaneh, AM, Brown, VI, Dahi, PB, Daly, A, Diaz, MA, Freytes, CO, Ganguly, S, Hashmi, S, Hildebrandt, GC, Lazarus, HM, Nishihori, T, Olsson, RF, Page, KM, Papanicolaou, G, Saad, A, Seo, S, William, BM, Wingard, JR, Wirk, B, Yared, JA, Perales, MA, Auletta, JJ, Komanduri, KV, Lindemans, CA & Riches, ML 2019, 'Increased overall and bacterial infections following myeloablative allogeneic HCT for patients with AML in CR1', Blood Advances, vol. 3, no. 17, pp. 2525-2536.
Naik, S, Riches, M, Hari, P, Kim, S, Chen, M, Bachier, C, Shaughnessy, P, Hill, J, Ljungman, P, Battiwalla, M, Chhabra, S, Daly, A, Storek, J, Ustun, C, Diaz, MA, Cerny, J, Beitinjaneh, A, Yared, J, Brown, V, Page, K, Dahi, PB, Ganguly, S, Seo, S, Chao, N, Freytes, CO, Saad, A, Savani, BN, Woo Ahn, K, Boeckh, M, Heslop, HE, Lazarus, HM, Auletta, JJ & Kamble, RT 2019, 'Survival outcomes of allogeneic hematopoietic cell transplants with EBV-positive or EBV-negative post-transplant lymphoproliferative disorder, A CIBMTR study', Transplant Infectious Disease, vol. 21, no. 5, e13145.


Ustun, C, Young, JAH, Papanicolaou, GA, Kim, S, Ahn, KW, Chen, M, Abdel-Azim, H, Aljurf, M, Beitinjaneh, A, Brown, V, Cerny, J, Chhabra, S, Kharfan-Dabaja, MA, Dahi, PB, Daly, A, Dandoy, CE, Dvorak, CC, Freytes, CO, Hashmi, S, Lazarus, H, Ljungman, P, Nishihori, T, Page, K, Pingali, SRK, Saad, A, Savani, BN, Weisdorf, D, Williams, K, Wirk, B, Auletta, JJ, Lindemans, CA, Komanduri, K & Riches, M 2019, 'Bacterial blood stream infections (BSIs), particularly post-engraftment BSIs, are associated with increased mortality after allogeneic hematopoietic cell transplantation', Bone Marrow Transplantation, vol. 54, no. 8, pp. 1254-1265.
Slayton, WB, Schultz, KR, Kairalla, JA, Devidas, M, Mi, X, Pulsipher, MA, Chang, BH, Mullighan, C, Iacobucci, I, Silverman, LB, Borowitz, MJ, Carroll, AJ, Heerema, NA, Gastier-Foster, JM, Wood, BL, Mizrahy, SL, Merchant, T, Brown, VI, Sieger, L, Siegel, MJ, Raetz, EA, Winick, NJ, Loh, ML, Carroll, WL & Hunger, SP 2018, 'Dasatinib plus intensive chemotherapy in children, adolescents, and young adults with philadelphia chromosome–positive acute lymphoblastic leukemia: Results of children’s oncology group trial AALL0622', Journal of Clinical Oncology, vol. 36, no. 22, pp. 2306-2313.
Brown, V 2018, Graft-versus-host disease. in The 5-Minute Pediatric Consult, 8th Edition. Wolters Kluwer Health, pp. 402-403.
Sholler, GLS, Ferguson, W, Bergendahl, G, Bond, JP, Neville, K, Eslin, D, Brown, V, Roberts, W, Wada, RK, Oesterheld, J, Mitchell, D, Foley, J, Parikh, NS, Eshun, F, Zage, P, Rawwas, J, Sencer, S, Pankiewicz, D, Quinn, M, Rich, M, Junewick, J & Kraveka, JM 2018, 'Maintenance DFMO Increases Survival in High Risk Neuroblastoma', Scientific reports, vol. 8, no. 1, 14445.
Lund, TC, Ahn, KW, Tecca, HR, Hilgers, MV, Abdel-Azim, H, Abraham, A, Diaz, MA, Badawy, SM, Broglie, L, Brown, V, Dvorak, CC, Gonzalez-Vicent, M, Hashem, H, Hayashi, RJ, Jacobsohn, DA, Kent, MW, Li, CK, Margossian, SP, Martin, PL, Mehta, P, Myers, K, Olsson, R, Page, K, Pulsipher, MA, Shaw, PJ, Smith, AR, Triplett, BM, Verneris, MR & Eapen, M 2019, 'Outcomes after Second Hematopoietic Cell Transplantation in Children and Young Adults with Relapsed Acute Leukemia', Biology of Blood and Marrow Transplantation, vol. 25, no. 2, pp. 301-306.

Clinical Trials Search

Children (age < 18 years)
Adults (age >= 18 years)